Market Place
Sourcing Support
Gilead To Present HIV Research Progress At AIDS 2024
16 Jul 2024 //
BUSINESSWIRE
FDA Approves Biktarvy® Label Update With Data for Pregnant Adults With HIV
26 Apr 2024 //
BUSINESSWIRE
Gilead Sciences Announces First Quarter 2024 Financial Results
26 Apr 2024 //
PRESS RELEASE
FDA Approves Expanded Indication for Gilead’s Biktarvy to Treat People with HIV
26 Feb 2024 //
BUSINESSWIRE
Real-World Evidence Reinforces Biktarvy® as Treatment Option for HIV
19 Oct 2023 //
BUSINESSWIRE
ViiV, Gilead row escalates to feds after self-regulation fails
02 May 2023 //
FIERCE PHARMA
Gilead receives EC marketing authorisation for HIV treatment in children
30 Nov 2022 //
PHARMACEUTICAL-TECHNOLOGY
EC Grants Expanded Marketing Authorization for Gilead’s Biktarvy
29 Nov 2022 //
BUSINESSWIRE
Gilead Presents Real-World Evidence Reinforcing the Use of Biktarvy
24 Oct 2022 //
BUSINESSWIRE
My Biggest Worry About Gilead Sciences
14 Sep 2022 //
FOOL
Gilead trumpets a Biktarvy win in HIV, hepatitis B co-infection
02 Aug 2022 //
FIERCEPHARMA
FDA expands approval to Gilead’s Biktarvy for paediatric HIV-1 treatment
19 Oct 2021 //
PHARMACEUTICAL-TECHNOLOGY
FDA Approves Expanded Indication of Gilead’s Biktarvy for HIV-1 in Pediatrics
18 Oct 2021 //
BUSINESSWIRE
Gilead’s HIV therapy Biktarvy demonstrates long-term sustained efficacy
08 Mar 2021 //
PHARMATIMES
Gilead’s Biktarvy sustains viral suppression and tolerability in Asian HIV
16 Oct 2020 //
BIOSPECTRUMASIA
Gilead Presents Biktarvy® Findings From Switch Studies & Analysis
05 Oct 2020 //
BIOSPACE
Gilead Presents Biktarvy Findings of Real-World BICSTaR Study At HIVGlasgow 2020
05 Oct 2020 //
BIOSPACE
UK marketing police slam Gilead for misleading Biktarvy promos
15 Jul 2020 //
FIERCE PHARMA
US Sues Gilead Over HIV Drug Patents
08 Nov 2019 //
RAPS
Gilead touts new data for fast-growing Biktarvy as older HIV meds show some cracks
07 Nov 2019 //
BUSINESSWIRE
Gilead riding Biktarvy success as HIV portfolio shows weakness
06 Nov 2019 //
FIERCE PHARMA
China NMPA approves Biktarvy to treat HIV-1 Infection
16 Aug 2019 //
BIOSPECTRUMASIA
China Approves Gilead HIV Drug Within 18 Months of EMA and FDA
13 Aug 2019 //
RAPS
China National Medical Products Administration Approves Biktarvy for HIV-1 Infe
09 Aug 2019 //
BUSINESSWIRE
Pfizer`s Xeljanz drops off top June TV spenders list
11 Jul 2019 //
FIERCE PHARMA
Merck`s Keytruda will capture industry`s top sales spot in 2024: report
05 Jun 2019 //
FIERCE PHARMA
J&J-backed AIDS film picked up by Verizon Media
10 May 2019 //
FIERCE PHARMA
UPDATE 1-Gilead to separate Kite cell therapy unit, posts higher profit
02 May 2019 //
CNBC
Gilead Presents New Data on (Bictegravir, Emtricitabine & Tenofovir Alafenamide)
06 Mar 2019 //
BUSINESSWIRE
Singapore HSA Approves Biktarvy for Treatment of HIV-1 Infection
13 Feb 2019 //
PR NEWSWIRE
GSK looks to oncology for growth as Advair generic hits
06 Feb 2019 //
FIERCE PHARMA
Before ‘JPM,’ here’s a cheat sheet for what to watch in biotech in 2019
02 Jan 2019 //
STAT NEWS
Gilead Announces Results From Phase 3 Study of Biktarvy
30 Oct 2018 //
BUSINESSWIRE
Gilead`s HIV portfolio soars, but HCV sales falling?
27 Oct 2018 //
FIERCE PHARMA
Gilead raises outlook despite dip in revenue
26 Oct 2018 //
PHARMA TIMES
Gilead Announces 96-Week Results From Ph 3 Study of Biktarvy
04 Oct 2018 //
Four new medicines available via NHS Scotland
12 Sep 2018 //
PHARMA TIMES
Gilead`s top execs Milligan and Martin stepping down
26 Jul 2018 //
FIERCE PHARMA
J&J joins blockbuster HIV combo race with newly approved 4-in-1 pill
19 Jul 2018 //
ENDPTS
Is Gilead Poised for a Comeback?
07 Jul 2018 //
BIOSPACE
